M. Rutstein

发表

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.

B. Bain, G. Mufti, D. Kuter, 2009, Blood.

Pharmacoepidemiology of anemia in kidney transplant recipients.

W. Winkelmayer, A. Chandraker, R. Kewalramani, 2004, Journal of the American Society of Nephrology : JASN.

2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome

M. Teufel, Tae Won Kim, S. Wilhelm, 2015 .

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

J. Guinney, M. Teufel, P. Wirapati, 2015 .

Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database

F. Mowat, J. Fryzek, Gena P Kucera, 2009, British journal of haematology.

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.

G. Sonpavde, M. Galsky, J. Gschwend, 2019, Future oncology.

9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

P. Stiff, M. Fanale, C. Moskowitz, 2009 .

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.

A. Wu, D. Cella, C. Snyder, 2009, Current medical research and opinion.

Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)

R. Govindan, S. Novello, E. Juhász, 2016 .

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences

A. Wu, D. Cella, C. Snyder, 2009 .

A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.

M. Meng, Sam S. Chang, J. Gschwend, 2019, Journal of Clinical Oncology.

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

M. Meng, Sam S. Chang, J. Witjes, 2019, European Urology Supplements.

A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).

G. Sonpavde, M. Galsky, J. Gschwend, 2019, Journal of Clinical Oncology.

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.

B. Bain, G. Mufti, D. Kuter, 2009 .

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.

B. Bain, G. Mufti, D. Kuter, 2009, Blood.

Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

L. Benjamin, R. Martell, E. Chiorean, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.

B. Bain, G. Mufti, D. Kuter, 2009, Blood.